Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 4

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 3
Chunk 4
---
 relate to our business are expensive and time consuming and their outcome is uncertain.
----------------------------------------------------------------------------------------------------------

●                                                     We                                                 
    may experience delays in our clinical trials that could adversely affect our business and operations.
---------------------------------------------------------------------------------------------------------

1

●                                                          We                                                       
    may not be able to complete the development of our products candidates or develop other pharmaceutical products.
--------------------------------------------------------------------------------------------------------------------

●                                                                We                                                             
    may need to prioritise the development of our most promising candidates at the expense of the development of other products.
--------------------------------------------------------------------------------------------------------------------------------

●                                                                    Our                                                                  
    research and development efforts will be seriously jeopardised if we are unable to retain key personnel and cultivate key academic and
                                                          scientific collaborations.                                                      
------------------------------------------------------------------------------------------------------------------------------------------

●                                                                     If                                                                  
    we are unable to successfully keep pace with technological change or with the advances of our competitors, our technology and products
                                                   may become obsolete or non-competitive.                                                
------------------------------------------------------------------------------------------------------------------------------------------

●                                                                    Acceptance                                                                 
    of our products in the marketplace is uncertain and failure to achieve market acceptance will negatively impact our business and operations.
------------------------------------------------------------------------------------------------------------------------------------------------

●                                                                      We                                                                   
          have limited large scale manufacturing experience with our product candidates. Delays in manufacturing sufficient quantities      
    of such materials to the required standards for non-clinical and clinical development may negatively impact our business and operations.
--------------------------------------------------------------------------------------------------------------------------------------------

●                                                                    The                                                                 
    failure to establish sales, marketing and distribution capability would materially impair our ability to successfully market and sell
                                                         our pharmaceutical products.                                                    
-----------------------------------------------------------------------------------------------------------------------------------------

●                                                                        If                                                                    
    healthcare insurers and other organisations do not pay for our products, or impose limits on reimbursement, our future business may suffer.
-----------------------------------------------------------------------------------------------------------------------------------------------

●                                       We                                    
    may be exposed to product liability claims, which could harm our business.
------------------------------------------------------------------------------

●                                                                 Breaches                                                             
    of network or information technology security, natural disasters or terrorist attacks could have an adverse effect on our business.
---------------------------------------------------------------------------------------------------------------------------------------
Risks Related to Government Regulation

●                                                                   If                                                               
    we do not obtain the necessary governmental approvals, we will be unable to develop or commercialise our pharmaceutical products.
-------------------------------------------------------------------------------------------------------------------------------------

●                                                                       We                                                                    
    will not be able to commercialise any current or future product candidates if we fail to adequately demonstrate their safety and efficacy.
----------------------------------------------------------------------------------------------------------------------------------------------

●                                                                     Positive                                                                  
    results in previous clinical trials of product candidates may not be replicated in future clinical trials, which could result in development
                                                 delays or a failure to obtain marketing approval.                                              
------------------------------------------------------------------------------------------------------------------------------------------------

●                                                                     Even                                                                  
    if approved, any product